EPS · actual vs est
$0.78 / $0.79Miss -1.3%
Revenue · actual vs est
$279.2M / $179.5MBeat +55.5%
Summary
Generated 2025-03-13
Management highlights
Management Statement and Operational Highlights
- Fourth Quarter Performance: Comparable sales increased 5.9%, total sales were $279 million. Operating profit doubled to $20 million, and EPS increased 95% to $0.78. The shortfall to initial guidance was due to lower sales in mid to late December in North America.
- Strategic Priorities 2025:
- Inject assortments with newness: Launched over 120 new brands in 2024, with new brands constituting a larger portion of sales.
- Private label expansion: Private label reached nearly 28% of total sales in 2024, up from 23% in 2023.
- Customer engagement: Focus on best-in-class service in stores and online, with investments in training and technology.
- Cost Management: Closed 31 underperforming locations, optimized store labor, reduced shipping and logistics costs, and decreased discount selling.
- Europe Performance: Sales were challenging in 2024 but improved in Q4, with product margins improving by over 100 basis points from the prior year.
Segment performance
Segment Performance
- North America: Comparable sales for the 13-week period ended February 1, 2025, were up 7.2%, marking the fourth consecutive quarter of growth. Full-year 2024 comparable sales were up 6.2%. Net sales in Q4 2024 were $214.2 million, and full-year net sales were $720 million.
- Other International (Europe and Australia): Q4 2024 comparable sales were up 1.9%, while full-year 2024 comparable sales were down 4.1% but improved in Q4. Net sales in Q4 2024 were $65 million, and full-year net sales were $169.2 million.
- Categories: Men's, women's, and footwear categories showed positive comparable sales growth; accessories and hard goods were negative. Private label reached nearly 28% of total sales in 2024, up from 23% in 2023.
Guidance
Guidance
- First Quarter 2025: Total sales expected to be between $179 million and $183 million (1-3% growth), comparable sales 3-5%. Product margin slightly down/flat. Operating loss预计 to be between negative $16.5 million and negative $18.5 million, and EPS预计 to be between negative $0.72 and negative $0.82.
- Full Year 2025: Expect to grow total sales despite store closures, aim to grow product margins, hold SG&A flat as a percentage of sales, plan to open 9 new stores (including 2 in Europe and 1 in Australia), and capital expenditures预计 to be between $14 million and $16 million.
Risks
Risks
- Tariffs: Impact on sourcing, particularly from China; need to diversify production to mitigate exposure.
- Macroeconomic Uncertainty: Volatile consumer purchasing patterns and uncertain macroeconomic environment posing risks to sales and profitability.
Q&A highlights
Question and Answer
- Q: Impact of tariffs on private label and brands, pricing. A: Sourcing strategy involves working with brands, with over 70% of business from brands. Currently diversifying production from China, with already moving production in 2025 to reduce reliance on China.
- Q: Leverage points and flow-through on EBITDA vs SG&A. A: Good opportunity in gross margin to grow product margin and leverage occupancy/distribution costs. SG&A expected to grow in line with sales; high flow-through (30%+) expected if sales exceed plan.
- Q: Growing operating margin with low single-digit comp. A: Yes, possible given ongoing efforts to manage costs and grow sales despite challenges.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $0.78 | $0.79 | -1.3% | $0.40 |
| Revenue | $279.2M | $179.5M | +55.5% | $281.8M |
Transcript
March 13, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.